Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $48
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Integra Lifesciences (NASDAQ:IART) and raises the price target from $44 to $48.
July 19, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Integra Lifesciences' price target has been raised from $44 to $48 by Truist Securities, while maintaining a 'Hold' rating.
The news is directly about Integra Lifesciences. The 'Hold' rating suggests that the analyst does not expect significant price movement in the short term. However, the increase in price target could be seen as a positive signal, potentially leading to a slight increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100